Phase II Clinical Study of Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favourable FcγR IIa (CD32) Genotype

Trial Profile

Phase II Clinical Study of Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favourable FcγR IIa (CD32) Genotype

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2016

At a glance

  • Drugs Cetuximab (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms MUTEX
  • Sponsors Merck KGaA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 May 2016 Dosing regimen is changed as follows:Patients were receiving an initial loading dose of cetuximab 400 mg/m2 for the first dose, then 250 mg/m2 for subsequent doses and now they will have 500 mg/m2 every 2 weeks.
    • 03 Jun 2015 Status changed from active, no longer recruiting to completed ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top